ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint744,814 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryZugAurealis Therapeutics AG
Aurealis Therapeutics AG Logo
Verified· 2 sources

Aurealis Therapeutics AG

Summary

About the company

The core activity of Aurealis Therapeutics is the development and marketing of bacteria-based cell and gene therapies for the treatment of chronic wounds and cancer. In particular, the company focuses on the development of proprietary technologies that use genetically modified Lactococcus cremoris bacteria to produce multiple human therapeutic proteins. The company's two leading clinical products are AUP-16 for chronic wounds and AUP-55 for cancer.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered4
Multi-target cell and gene therapies
Multi-target cell and gene therapies for chronic wounds, cancer and inflammatory diseases, based on a modular bacterial platform using genetically engineered Lactococcus cremoris.
Therapy for chronic wounds (AUP-16)
Topical multi-target gene therapy for diabetic foot ulcers, venous leg ulcers and pressure/rare ulcers; Phase 2 in diabetic foot ulcers completed, further indications in development.
Oncology therapy (AUP-55)
Oncolytic, bacterial-based ATMPs for ovarian, peritoneal, bladder and recurrent melanoma; preclinical data and intratumoral administration described in the programme.
Partnerships, licensing and co-development
Strategic partnerships, licensing and co-development for AUP-16, AUP-55 and the 4-in-1 platform; including regional and global development and marketing rights.

Knowledge

No knowledge articles yet

Once Aurealis Therapeutics AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Aurealis Therapeutics AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Aurealis Therapeutics AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Aurealis Therapeutics AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Baarerstrasse 21
6300 Zug

At a glance

Legal form
Corporation
UID
CHE-222.498.046
Founded
2018 · 8 years
Last commercial register change
June 11, 2025
Employees
21 to 50

Similar companies

AP
Azurity Pharmaceuticals Switzerland GmbH
Zug
AP
Aphaia Pharma AG
Zug
BS
Bristol-Myers Squibb Products SA
Steinhausen
BI
Biogen International GmbH
Baar